drug

(redirected from Disease-modifying antirheumatic drug)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.

drug

noun alterant, analgesic, anesthetic, anesthetic agent, anodyne, antibiotic, chemical substance, curative preparation, medical preparation, medicament, medication, medicinal component, medicinal innredient, narcotic preparation, narcotic substance, opiate, painkiller, palliative, physic, prescription, remedy, sedative, soporific, stimulant, stupefacient
Associated concepts: adulterated drugs, dangerous drugs, drug addiction, habit-forming drug, influence of drugs, laaeling of drugs, poisonous drugs or chemicals, possession of drugs, preparation of drugs, prescription drugs, regulaaion of drugs, sale of drugs

drug

verb administer, anesthetize, anoint, apply a remedy, benumb, cure, deaden, desensitize, dose, dull, heal, inject, medicare, medicate, narcotize, numb, palliate, physic, poultice, prescribe, put to sleep, stun, stupefy, treat
Associated concepts: drug addicts
References in periodicals archive ?
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
In rheumatoid arthritis, the recommendation from the American College of Rheumatology is for early, aggressive intervention with disease-modifying antirheumatic drugs, often within a few months of the onset of the disease.
In addition to the combination disease-modifying antirheumatic drug (DMARD) regimen, patients received placebo or infliximab in doses of 3 mg/kg at weeks 4, 6, 10, 18, and 26, and were followed for 2 years.
Screening for both hepatitis C and B is a reasonable strategy in all patients who are under consideration for any disease-modifying antirheumatic drug.
None had prior disease-modifying antirheumatic drug (DMARD) treatment.
The trial is a non-inferiority design and it randomised 1,262 patients with moderately to severely active RA who have not had an adequate response to disease-modifying antirheumatic drug (DMARD) therapies which may have included (in up to 20% of patients) one or more tumour necrosis factor (TNF) antagonist therapies into two treatment arms.
No other significant associations were seen, including current use of tumor necrosis factor blockers, disease-modifying antirheumatic drug, or corticosteroids.
A little more than 90% of the patients in each group used disease-modifying antirheumatic drugs during the study.
6%) of past cancer among 3,236 people whose RA was treated with traditional disease-modifying antirheumatic drugs (DMARDs) at 32 U.
It is indicated for reducing the signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis (JRA) in those who have had an inadequate response to one or more disease-modifying antirheumatic drugs.